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Abstract
Background:  Human T-lymphotropic virus type 1 (HTLV-1) proviral load is related to the
development of HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) and has
also been shown to be elevated in the peripheral blood in HTLV-1-infected patients with uveitis or
alveolitis. Increased proliferation of HTLV-1-infected cells in, or migration of such cells into, the
central nervous system is also seen in HAM/TSP. In the present study, we evaluated the proviral
load in a cohort of HTLV-1-infected patients with arthritic conditions.
Results: HTLV-1 proviral load in the peripheral blood from 12 patients with RA and 6 patients
with connective tissue disease was significantly higher than that in matched asymptomatic HTLV-1
carriers, but similar to that in matched HAM/TSP controls. HAM/TSP was seen in one-third of the
HTLV-1-infected patients with RA or connective tissue disease, but did not account for the higher
proviral load compared to the asymptomatic carrier group. The proviral load was increased in the
synovial fluid and tissue from an HTLV-1-infected patient with RA, the values suggesting that the
majority of infiltrated cells were HTLV-1-infected. In the peripheral blood from HTLV-1-infected
patients with RA or connective tissue disease, HTLV-1 proviral load correlated with the
percentages of memory CD4+ T cells and activated T cells, and these percentages were shown to
be markedly higher in the synovial fluid than in the peripheral blood in an HTLV-1-infected patient
with RA.
Conclusions:  These biological findings are consistent with a role of the retrovirus in the
development of arthritis in HTLV-1-infected patients. A high level of HTLV-1-infected lymphocytes
in the peripheral blood and their accumulation in situ might play a central role in the pathogenesis
of HTLV-1-associated inflammatory disorders. Alternatively, the autoimmune arthritis, its
etiological factors or treatments might secondarily enhance HTLV-1 proviral load.
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Background
Human T-lymphotropic virus type 1 (HTLV-1) is endemic
in southern Japan, intertropical Africa, Melanesia, Latin
America, and the Caribbean basin [1]. HTLV-1 is the etio-
logical agent of adult T-cell leukemia [2] and HTLV-1-
associated myelopathy/tropical spastic paraparesis
(HAM/TSP), an inflammatory disease of the central nerv-
ous system [3,4], and has also been implicated in several
other inflammatory disorders, such as polymyositis [5],
uveitis [6], Sjögren's syndrome [7], alveolitis [8], and
infective dermatitis [9].
The possibility that HTLV-1 may cause joint disease was
initially raised by reports of arthralgia and polyarthritis in
patients with adult T-cell leukemia [10,11]. Polyarthritis
has also been observed in some patients with HAM/TSP
[12]. Nishioka et al. [13] described the association of a
polyarthritis syndrome with HTLV-1 infection in the
absence of clinical ATL or HAM/TSP, and proposed the
term HTLV-1-associated arthritis (HAA). Cases of HTLV-1-
infected patients with mixed connective tissue disease
have also been described [14], although an association
between HTLV-1 infection and systemic lupus erythema-
tosus has not been established [15]. Apart from the possi-
bility of neurological signs, the clinical features of HAA
are similar to those of idiopathic rheumatoid arthritis
(RA) [16-18]. Epidemiological studies have demonstrated
that HTLV-1 seropositivity is a risk factor for RA in Japan
[19,20], but a recent study conducted in South Africa,
another HTLV-1 endemic area, failed to detect any associ-
ation between HTLV-1 and RA [21]. This discrepancy
might be due to differences in genetic background,
although the possibility cannot be excluded that HAA in
Japan results from the coincidental coexistence of two rel-
atively common diseases. Interestingly, a recent prospec-
tive study demonstrated an increased incidence of arthritis
in cohorts of former US blood donors infected with
HTLV-1 or HTLV-2 [22].
Several findings support the hypothesis of an etiopatho-
genic role for HTLV-1 in HAA: ATL-like T lymphocytes
have been identified in the synovial fluid and synovial tis-
sue [17,18,23]; high titers of IgM antibodies against
HTLV-1 have been found in the synovial fluid [23]; HTLV-
1 proviral DNA has been detected in synovial fluid cells
and synovial tissue cells [23], cultured adherent synovial
stromal cells [24], and synovial macrophage cells [25];
and Tax mRNA and protein have been detected in syno-
vial stromal cells [26]. HTLV-1 tropism for synovial cells
has been confirmed in vitro [27]. Moreover, mice trans-
genic for Tax develop an inflammatory arthropathy
resembling RA in humans [28]. The development and
progression of RA is dependent on the migration of T lym-
phocytes into the synovial compartment [29,30]. Simi-
larly, the tissue damage in HAM/TSP is thought to be
caused by T cells that have infiltrated the central nervous
system [31,32]. T lymphocytes, especially CD4+ T cells, are
the main target of HTLV-1 in vivo and carry the majority
of the HTLV-1 proviral load [33]. The HTLV-1 proviral
load in peripheral blood mononuclear cells (PBMCs) is
higher in patients with HAM/TSP than in asymptomatic
HTLV-1 carriers [34] and the equilibrium set point of the
proviral load is suspected to determine the development
of the disease [35].
We postulated that HTLV-1 proviral load might also influ-
ence the initiation and course of HAA, and measured this
marker in PBMCs from a previously described cohort [16]
of HTLV-1-infected patients with RA and in a group of
HTLV-1-infected patients with connective tissue disease.
Results
The HTLV-1 proviral load was measured in the peripheral
blood of HTLV-1-infected patients with RA or connective
tissue disease and in matched asymptomatic and HAM/
TSP controls (Figure 1). The number of copies of HTLV-1
proviral DNA per 106 PBMCs ranged from 14,600 to
HTLV-1 proviral load in the peripheral blood from HTLV-1- infected patients with RA or connective tissue disease and  from HAM/TSP or asymptomatic controls Figure 1
HTLV-1 proviral load in the peripheral blood from 
HTLV-1-infected patients with RA or connective tis-
sue disease and from HAM/TSP or asymptomatic 
controls. The 10th and 90th percentiles are shown as the 
lower and upper horizontal bars on the vertical line, while 
the 25th and 75th percentiles are shown as the lower and 
upper edges of the box; the median is shown within the box. 
The results shown as dots fall outside the 10th and 90th 
percentiles.
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373,000 in the patients with RA (Table 1) and from 1,500
to 411,200 in patients with connective tissue disease
(Table 2), the corresponding ranges in the HTLV-1 asymp-
tomatic carriers and in patients with HAM/TSP being 50
to 97,700 and 2,100 to 392,000, respectively. The mean ±
SD and median proviral loads were 133,800 ± 134,600
and 75,800 in the HTLV-1-infected patients with RA or
connective tissue disease combined, the values for the RA
subgroup being 114,400 ± 112,200 and 67,400 and those
for the connective tissue disease subgroup 172,500 ±
176,700 and 120,800, while the corresponding values in
the asymptomatic carriers were 18,800 ± 26,400 and
10,100 and those in patients with HAM/TSP 86,800 ±
90,600 and 62,400. The HTLV-1 proviral load was signif-
icantly higher in the HTLV-1-infected group with RA or
connective tissue disease than in the matched asympto-
matic HTLV-1 carriers (P = 0.0012 in Wilcoxon's test, P =
0.0002 in the paired t-test after log-transformation), and
the difference remained significant when the analysis
focused on the RA subgroup (P = 0.0022 in Wilcoxon's
test, P = 0.0002 in the paired t-test). No differences were
observed between the HTLV-1-infected group with RA or
connective tissue disease and the matched HAM/TSP con-
trols (P > 0.05 in both Wilcoxon's test and the paired t-
test). As expected, the difference between the asympto-
matic carriers and the HAM/TSP group was significant (P
Table 1: Clinical and biological features of HTLV-1-infected patients with RA
Patient Sex Age Associated 
Diseases
Disease 
duration (year)
Sharp 
score
ESR (mm) CRP (mg/l) RF (IU/ml) Treatment HTLV-1 proviral load 
(copies / 106 PBMCs)
1 F 75 - 7 65 111 313 128 Corticosteroids, 
DMARDs
373,300
2 F 63 HAM/TSP 2 10 70 5 32 Corticosteroids, 
DMARDs
39,800
3 F 62 - 9 3 41 6 - NSAIDs 126,500
4 F 58 - 7 46 5 3 64 Corticosteroids, 
DMARDs
55,000
5 F 72 - 7 109 56 16 - NSAIDs, DMARDs 38,500
6 F 59 - 10 5 38 5 - Corticosteroids, 
DMARDs
28,900
7 F 64 - 2 8 25 12 128 Corticosteroids, 
DMARDs
79,800
8 F 69 - 16 126 21 30 16 Corticosteroids, 
DMARDs
230,000
9 F 57 HAM/TSP 13 6 29 13 - Corticosteroids 247,400
10 F 58 HAM/TSP 2 17 35 9 32 Corticosteroids, 
DMARDs
106,500
11 F 42 - 18 3 22 5 - Analgesics 32,200
12 F 77 HAM/TSP 7 110 88 41 - Corticosteroids, 
DMARDs
14,600
Sharp score : joint space narrowing score and erosion score; CRP: C-reactive protein; ESR, erythrocyte sedimentation rate; RF: rheumatoid factor; 
NSAIDs: non-steroidal anti-inflammatory drugs; DMARDs: disease-modifying anti-rheumatic drugs (hydroxychloroquine, leflunomide, 
methotrexate, etc.)
Table 2: Clinical and biological features of HTLV-1-infected patients with connective tissue disease
Patient Sex Age Connective 
tissue disease
Associated 
diseases
Disease 
duration (year)
ESR (mm) CRP (mg/l) ANA Treatment HTLV-1 proviral 
load (copies / 106 
PBMCs)
13 F 38 SLE uveitis 13 38 6 + Corticosteroids, HC 18,400
14 F 68 PM - 1 17 1 + Corticosteroids 411,200
15 F 60 SS - 2 10 1 + NSAIDs, HC 1,500
16 F 56 PM HAM/TSP 10 17 12 + Corticosteroids 71,700
17 F 63 SS - 3 22 15 + NSAIDs, HC 169,900
18 F 65 SS HAM/TSP, 
alveolitis
5 21 1 - Corticosteroids 362,300
SS, Sjögren's syndrome, SLE : Systemic lupus erythematosus, PM : Polymyositis, ANA: anti-nuclear antibodies; HC : hydroxychloroquineRetrovirology 2005, 2:4 http://www.retrovirology.com/content/2/1/4
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= 0.0001 in Wilcoxon's test, P < 0.0001 in the paired t-
test).
Of the 12 HTLV-1-infected patients with RA, 4 (patients 2,
9, 10, and 12) had HAM/TSP (Table 1); their respective
HTLV-1 proviral loads were 39,800, 247,400, 106,500,
and 14,600 copies per 106 PBMCs. Two patients with
connective tissue disease (Table 2, patients 16 and 18)
had HAM/TSP, which was associated with alveolitis in
patient 18, with proviral loads of 71,600 and 362,300.
These samples did not account for the higher proviral load
in the arthritic group compared to the asymptomatic car-
rier group. Indeed, after excluding the patients with co-
existing HAM/TSP, the difference between the asympto-
matic controls and the group with RA or connective tissue
disease remained significant (P = 0.0121, Wilcoxon's test;
P = 0.0027, paired t-test), even when the analysis was
restricted to the subgroup with RA alone (P = 0.0117, Wil-
coxon's test; P = 0.0003, paired t-test). The patient with
connective tissue disease and uveitis (patient 13) had
18,420 copies per 106 PBMCs. For one of the patients with
RA and HAM/TSP (patient 10), 4 consecutive frozen dry
pellets of PBMCs from 1996 to 2002 were available; in
these, the proviral load was relatively stable at 92,100,
73,600, 143,300, and 106,500 copies per 106  cells,
respectively.
No correlation was found between HTLV-1 proviral load
and the age of the patient, the duration of illness, or the
Ritchie's index score (P > 0.05, Spearman test). HTLV-1
proviral load did not correlate with erythrocyte sedimen-
tation rate or C-reactive protein level (P > 0.05, Spearman
test). No significant difference in HTLV-1 proviral load
was seen in patients positive or negative for rheumatoid
factor or antinuclear antibody (P > 0.05, Mann-Whitney
test) or receiving or not receiving either specific treatments
for RA or corticotherapy (P > 0.05, Mann-Whitney test).
The proviral load was measured in two sets of PBMCs and
synovial fluid or synovial tissue cells obtained from one
HTLV-1-infected patient with RA at an interval of one year
(Table 1, patient 5). In the first set of samples, the HTLV-
1 proviral load in the synovial fluid cells and paired
PBMCs was 845,200 and 125,300 copies per 106 cells,
respectively, while, in the second set of samples from a
year later, the proviral load in the synovial tissue cells and
paired PBMCs was 666,700 and 38,500 per 106 cells,
respectively.
Lymphocytes subsets and activation status were examined
in the peripheral blood of HTLV-1-infected patients with
RA or connective tissue disease. When correlations were
examined between HTLV-1 proviral load and the percent-
age of T lymphocytes expressing CD45RO, CD45RA, or
HLA-DR in the HTLV-1 infected patients with RA or con-
nective tissue disease (Figure 2), HTLV-1 proviral load cor-
related positively with the percentage of CD4+ T cells
expressing CD45RO and negatively with that of CD4+ T
cells expressing CD45RA (P = 0.039 and P = 0.021, Spear-
man test). A positive correlation was found between
HTLV-1 proviral load and the percentage of CD4+ T cells
expressing HLA-DR (P = 0.008), while the correlation did
not reach significance for CD8+ HLA-DR T cells.
Lymphocyte distribution and activation were compared
in the peripheral blood and synovial fluid of one HTLV-1-
infected patient with RA (patient 5). The percentage of
CD4+ T cells expressing CD45RO was dramatically
increased in the synovial fluid (98%) compared to the
peripheral blood (48%), as was the percentage of CD4+ T
lymphocytes expressing HLA-DR (94% compared to
18%).
Discussion
The etiology of autoimmune diseases, such as RA or
mixed connective tissue disease, has yet to be established,
but appears to result from complex interactions between
host genetic and environmental factors [36], and retrovi-
ruses have been considered as possible causative factors
[37]. HTLV-1 has been suggested to be implicated in the
pathogenesis of RA in Japan, where this retrovirus is
endemic [13,17,18]. Epidemiological studies have shown
an association between HTLV-1 infection and RA in Japan
[19,20], and between HTLV-1/2 infection and arthritis in
the United States [22]. HTLV-1-seropositive cases with
connective tissue disease have also been described,
although the authors suggested a geographical, rather
than an etiological, link [14]. Another study failed to dem-
onstrate any association between HTLV-1 infection and
systemic lupus erythematosus in Jamaica [15]. Consider-
ing the age, sex ratio, and HTLV-1 prevalence (4.6%) in
our RA cohort, a fortuitous coincidence cannot be
excluded. The prevalence of HTLV-1 infection in Marti-
nique is estimated to be around 1.5% and increases with
age, particularly among women [38]. An epidemiological
study is therefore required to determine whether there is
no, or a weak, association between HTLV-1 and arthritis in
Martinique.
Nevertheless, the present study provides biological data
suggesting a contribution of HTLV-1 to the development
of some cases of RA or mixed connective tissue disease.
We found that: (1) The circulating HTLV-1 proviral load
was higher in HTLV-1-seropositive patients with RA or
connective tissue disease than in asymptomatic HTLV-1
carriers and similar to that in patients with HAM/TSP; (2)
In the peripheral blood of patients with arthritis, HTLV-1
proviral load correlated with the percentage of memory
and activated T CD4+ cells; (3) A high HTLV-1 proviral
load was found in the synovial fluid and tissue cells in aRetrovirology 2005, 2:4 http://www.retrovirology.com/content/2/1/4
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patient with RA; (4) In this patient, the percentage of
memory and activated CD4+ T cells was higher in the syn-
ovial compartment than in the peripheral blood.
The HTLV-1 proviral load is thought to be a major deter-
minant of HTLV-1-associated diseases. The HTLV-1 provi-
ral load is higher in the peripheral blood from patients
with HAM/TSP than in blood from asymptomatic carriers
[34]. It is also higher in the peripheral blood of patients
with HTLV-1-associated uveitis than in asymptomatic car-
riers [39,40]. Similarly, we observed a significantly higher
proviral load in HTLV-1-infected patients with either RA
or connective tissue disease than in HTLV-1 asymptomatic
carriers. Moreover, the proviral load was higher in the syn-
ovial fluid and tissue from one HTLV-1-infected patient
with RA than in the peripheral blood. Assuming an aver-
age of one HTLV-I provirus per infected cell, the proviral
load values in these synovial samples suggest that the
majority of infiltrated cells are infected. HTLV-1 proviral
load is known to be higher in the spinal fluid than in
paired blood samples from HAM/TSP [41,42], but not
asymptomatic carriers [43]. Interestingly, a higher HTLV-
1 proviral load than in the peripheral blood has also been
reported in bronchoalveolar lavage fluid in patients with
HTLV-1-associated alveolitis [44] and in the labial salivary
glands in patients with HTLV-1-associated Sjögren's syn-
drome [45,46]. Thus, a high proviral load might be
involved in the pathogenesis of several other HTLV-1-
associated inflammatory disorders in addition to HAM/
TSP.
In HAM/TSP, the HTLV-1 proviral load reaches an equilib-
rium set-point that is correlated with progression of
motor disability, and fluctuates by no more than 2- to 4-
Correlation between HTLV-1 proviral load, and memory or activated T lymphocytes subsets in the peripheral blood from  HTLV-1-infected patients with RA or connective tissue disease Figure 2
Correlation between HTLV-1 proviral load, and memory or activated T lymphocytes subsets in the peripheral blood from 
HTLV-1-infected patients with RA or connective tissue disease.
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fold over a decade [35]. In one HTLV-1-infected patient
with RA, the proviral load was found to be stable over a 6
year period. In HTLV-1-associated uveitis, the proviral
load has been shown to correlate with disease activity
[40]. However, in our cohort, HTLV-1 proviral load in the
peripheral blood did not correlate with disease activity
and was not influenced by treatment of the rheumatolog-
ical disease. This suggests that HTLV-1 proviral load
reaches a set-point determining the onset of the
rheumatological disease, but the intensity of the symp-
toms might be influenced by subsequent in situ events.
The unusually high proviral loads in HTLV-1 infection
results mainly from the Tax-driven activation and expan-
sion of infected cells [47]. The HTLV-1 targets are mainly
CD45RO-expressing CD4+ T lymphocytes and the proviral
load is reported to correlate with the number of memory
T cells [48]. In our HTLV-1-infected cohort with RA or
connective tissue disease, HTLV-1 proviral load correlated
positively with the percentage of CD4+ T cells expressing
CD45RO and negatively with that of CD4+ T cells express-
ing CD45RA. The HTLV-1 proviral load also correlated
positively with the percentage of HLA-DR-expressing T
cells. Migration of HTLV-1-infected CD4+  T cells and
HTLV-1-specific CD8+ cytotoxic T lymphocytes (CTL) into
the central nervous system is a critical step in the patho-
genesis of HAM/TSP [31,32]. Similarly, infiltration of T
cells plays a central role in the initiation and perpetuation
of RA [29,30]. Thus, our finding of an increase in memory
(CD45RO) and activated (HLA-DR) CD4+ T cells in the
joint fluid of an HTLV-1 carrier with RA supports the
hypothesis of a pathogenic involvement of HTLV-1-
infected T lymphocytes.
Several mechanisms are potentially involved in the occur-
rence of rheumatological disorders during HTLV-1 infec-
tion. Firstly, HTLV-1 infection upregulates the expression
of adhesion molecules potentially involved in the migra-
tion of lymphocytes into the spinal and joint compart-
ments [17]. Secondly, HTLV-1 might be transmitted from
the infiltrated T lymphocytes to the synoviocytes [23-26],
and subsequent Tax expression might induce proliferation
of these cells. Extracellular Tax protein has also been
reported to stimulate the proliferation of synoviocytes
[49]. Finally, Tax expression stimulates the production of
a variety of cytokines, including IL-15 and its receptor. IL-
15 might represent a cornerstone between HAM/TSP and
HTLV-1-associated rheumatological diseases. IL-15 favors
T cell migration into the target tissue compartment [50].
Moreover, IL-15 inhibits IL2-mediated activation-induced
cell death, and is suspected to both facilitate the persist-
ence of MHC I restricted memory CD8+ T cells involved
in the pathogenesis of HAM/TSP, and enhance the sur-
vival of self-reactive T cells, leading to the development of
autoimmune disease [51]. Recent data argue for a possible
autoimmune mechanism of tissue damage in HAM/TSP
[52]. Moreover, IL-15 can also induce TNF-α synthesis by
macrophages, which, in turn, stimulates a cascade of
proinflammatory cytokines, including IL-1β, IL-6, and
GM-CSF [50,53], which induce synoviocyte proliferation
and are thought to be deleterious for the central nervous
system [31]. Thus, the coexistence of HAM/TSP in one-
third of the HTLV-1-infected patients with RA might be
explained by the shared features of a high proviral load
and common downstream pathways. Alternatively,
autoimmune arthritis or its etiological factors might sec-
ondarily enhance HTLV-1 proviral load through cell
activation, with subsequent migration of HTLV-1-infected
cells into the joint or CNS. The accumulation of HTLV-1-
infected lymphocytes in the synovium could result from
selective infiltration and/or from oligoclonal expansion
once the PBMCs have infiltrated the joint. Whether the
increase in HTLV-1-infected cells in the peripheral blood
and the even greater increase in the synovial compartment
are the cause or an effect of the associated arthritis remains
uncertain. A role of the anti-inflammatory and anti-rheu-
matic drugs can also not be excluded.
In conclusion, our data in HTLV-1-infected patients with
RA or connective tissue disease are consistent with a role
of the proviral load in the development of these rheuma-
tological disorders, although the direction of causality in
this interaction remains open to question. HTLV-1 might
cause a systemic immune-mediated inflammatory disease
potentially involving tissues other than the central nerv-
ous system, HAM/TSP being only the major syndrome.
The clinical expression of this disease might be deter-
mined by the amount of HTLV-1-infected T lymphocytes,
their level of activation, and their capacity to accumulate
in different body compartments. Further research is
needed to increase our knowledge of the molecules
involved in the homing of HTLV-1-infected CD4+ T lym-
phocytes and of anti-HTLV-1-specific CD8+ CTL to differ-
ent target tissues.
Materials and Methods
Patients
The study was performed in Martinique, an island in the
lesser Antilles archipelago, with a population of 400,000.
Between 1988 and 2001, 280 patients with RA, defined
according to the American Rheumatology Association
(ARA) criteria, and 335 patients with connective tissue
disease were followed on an inpatient or outpatient basis
at the Rheumatology Department of the Regional Teach-
ing Hospital. Thirteen (4.6%) of the 280 patients with RA
(1 male and 12 female) were found to be HTLV-1 serop-
ositive, confirmed by Western blotting (antibodies recog-
nizing at least rgp21, p19, and p24) and peripheral blood
was obtained from 12 of these. In addition, 6 patients
with connective tissue disease (three with Sjögren's syn-Retrovirology 2005, 2:4 http://www.retrovirology.com/content/2/1/4
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drome, two with inflammatory myopathy, and one with
systemic lupus), who were seropositive for HTLV-1, were
included in the study. Samples were collected between
September 2001 and June 2002. For one patient, sequen-
tial samples cryopreserved since 1996 were available.
The mean age at the time of sampling was 63 years for the
HTLV-1-seropositive RA patients compared to 60 years for
the total RA cohort, while the mean age of the HTLV-1-
seropositive patients with connective tissue disease was 58
years. The mean time interval between onset of the auto-
immune disease and sampling for HTLV-1 proviral load
determination were 8 years and 6 years in the patients
with RA and connective tissue disease, respectively. Of the
12 HTLV-1-seropositive RA patients, 4 had HAM/TSP,
defined according to the WHO guidelines [54]. Two of the
patients with connective tissue disease also presented
HAM/TSP. The clinical and biological features of the
HTLV-1-infected patients with either RA or connective tis-
sue disease are summarized in Tables 1 and 2,
respectively.
Each HTLV-1-infected patient with RA or connective tissue
disease was matched for age (± 5 years) and sex with 2
patients with HAM/TSP and 2 asymptomatic HTLV-1
carriers.
Measurement of HTLV-1 proviral load
PBMCs were isolated from EDTA blood by density gradi-
ent centrifugation. Synovial fluid samples were obtained
by arthrocentesis and synovial tissue was obtained during
arthroscopy. The synovial tissue was minced into small
pieces, washed with phosphate-buffered saline, and
passed through a wire mesh to collect synovial tissue cells.
Cells were cryopreserved until use.
DNA was extracted from 106 cells using a phenol/chloro-
form procedure. The HTLV-1 proviral load was quantified
using a real-time TaqMan PCR method [55]. SK110/
SK111 primers were used to amplify a 186 bp fragment of
the pol gene and the dual-labeled TaqMan probe (5' FAM
and 3' TAMRA) was located at 4829–4858 bp of the
HTLV-1 reference sequence (HTLVATK). Albumin DNA
was quantified in parallel to determine the input cell
number and was used as an endogenous reference to nor-
malize variations due to differences in the PBMC count or
DNA extraction. For both HTLV-1 and the albumin gene,
amplifications were performed on 10 µl of DNA extract
using the TaqMan PCR Core Reagent kit, data being
acquired with the ABI Prism 7700 Sequence Detector Sys-
tem (Perkin Elmer, Foster City, California, USA). Standard
curves were generated using ten-fold serial dilutions of a
double standard plasmid (pcHTLV-ALB) containing one
copy of the target regions of both the HTLV-1 pol gene and
the cellular albumin gene. The HTLV-1-infected human
lymphocyte line MT2 (ECACC 93121518) was used as a
control for quantification, the limit for an acceptable
result being taken as 2.4–3.3 copies of the HTLV-1 pol
gene per cell and the variation between series being nor-
malized on the basis of three copies per MT2 cell. All
standard dilutions and control and patient samples were
run in duplicate for both HTLV-1 and albumin DNA
quantification. Standard curves for HTLV-1 and albumin
were accepted when the slope was between -3.322 and -
3.743 (corresponding to amplification efficiencies of
100% to 85%) and the correlation coefficient, r2, was
>0.992. If the variation between duplicate values of HTLV-
1 or albumin DNA copy numbers was greater than 30%,
the analysis was repeated. The normalized value for the
HTLV-1 proviral load was reported as the HTLV-1 average
copy number/albumin average copy number ratio × 106
and expressed as the number of HTLV-1 copies per 106
PBMCs.
Determination of CD4- and CD8-positive lymphocyte 
counts
Lymphocyte subsets in PBMCs were characterized using a
panel of labeled anti-human monoclonal antibodies,
consisting of fluorescein isothiocyanate-conjugated anti-
CD3 (clone SK7, mouse IgG1), allophycocyanin-conju-
gated anti-CD4 (clone SK3, mouse IgG1), peridinin chlo-
rophyll protein-conjugated anti-CD8 (clone SK1, mouse
IgG1), phycoerythrin (PE)-conjugated anti-CD45RO
(clone UCHL-1, mouse IgG2a), and PE-conjugated anti-
HLA-DR (clone L243, mouse IgG2a) (all from BD Bio-
sciences Immunocytometry Systems, San Jose, CA), and
PE-conjugated anti-CD45RA (Hl100 mouse IgG2b, from
BD Biosciences Pharmingen). The analyses were per-
formed on a FACSCalibur (BD Biosciences Immunocy-
tometry Systems).
Statistical analysis
Mann-Whitney's  U  test, Wilcoxon's signed rank test,
paired Student's t-test, and Spearman's rank correlation
were used, as appropriate. A P value < 0.05 was considered
to be statistically significant.
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